ストックスクリーナーアプリを入手
0.1988
11.96%
-0.027
アフターアワーズ：
.20
0.0012
+0.60%
前日終値:
$0.2258
開ける：
$0.2236
24時間の取引高:
3.39M
Relative Volume:
0.52
時価総額：
$181.17M
収益：
$420.00K
当期純損益:
$-35.84M
株価収益率:
-0.0335
EPS:
-5.9381
ネットキャッシュフロー:
$-32.12M
1週間 パフォーマンス:
+11.81%
1か月 パフォーマンス:
-29.00%
6か月 パフォーマンス:
-85.90%
1年 パフォーマンス:
-94.37%
1日の値動き範囲:
$0.19
$0.2236
1週間の範囲:
$0.1726
$0.237
52週間の値動き範囲:
$0.1455
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Compare KALA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.1988 | 205.78M | 420.00K | -35.84M | -32.12M | -5.9381 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-30 | ダウングレード | Mizuho | Outperform → Neutral |
| 2025-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-29 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2025-09-08 | 開始されました | Mizuho | Outperform |
| 2025-07-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-03-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-14 | ダウングレード | Jefferies | Buy → Hold |
| 2020-07-23 | 開始されました | Northland Capital | Outperform |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-09 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 開始されました | Jefferies | Buy |
すべてを表示
Kala Bio Inc (KALA) 最新ニュース
Kala Bio Transitions to AI-Powered Biotech Solutions with Researgency Platform and MSC-S Asset Strategy 47 - Minichart
KALA BIO: Q4 Earnings Snapshot - kens5.com
Eye-drug setback pushes KALA BIO (NASDAQ: KALA) toward high-risk AI bet - Stock Titan
Kala Bio rises on plans to leverage AI - MSN
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Earnings Risk: What is KALA BIO Incs market position2026 Levels & Growth Focused Stock Reports - baoquankhu1.vn
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
Kala Pharmaceuticals Inc (27F0.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com India
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kala Bio engages advisor to review clinical assets, AI analytics By Investing.com - Investing.com South Africa
KALA SEC FilingsKala Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kala Bio Delays 2025 Annual Report Filing - The Globe and Mail
KALA BIO, Inc. (KALA) stock price, news, quote and history - Yahoo Finance UK
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Kala Bio engages advisor to review clinical assets, AI analytics - Investing.com
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities - manilatimes.net
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and ... - Caledonian Record
Kala Bio (NASDAQ: KALA) notifies SEC of late 2025 10‑K, cites turnover - Stock Titan
Bionic Intelligence Research Agent Now Commercially Live for Secure, Scalable, Autonomous Solutions in Global Biotech and Pharma Industries: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
Bionic Intelligence Research Agent Now Commercially Live - openPR.com
User - The Chronicle-Journal
Kala Bio deploys AI research agent for biotech clients By Investing.com - Investing.com South Africa
Kala Bio Announces Initial Commercial Deployment of Bionic Intelligence Research Agent - marketscreener.com
Exclusive: Penny stock Kala Bio transitions to revenue model with AI platform launch - MSN
Kala Bio deploys AI research agent for biotech clients - Investing.com
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live - The Manila Times
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform LaunchKala Bio (NASDAQ:K - Benzinga
KALA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
KALA BIO Inc expected to post a loss of $1.44 a shareEarnings Preview - TradingView
KALA BIO, Inc. (NASDAQ:KALA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Trading Action: Will KALA BIO Inc stock benefit from M A2026 Selloffs & Daily Entry Point Trade Alerts - baoquankhu1.vn
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 600.0% in March - MarketBeat
If You Invested $1,000 in Kala Pharmaceuticals Inc (KALA) - Stock Titan
$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - Barchart.com
FinancialContent$180 Billion AI Healthcare Emerging Sector Highlighted by Red Light Holland’s Researgency.ai Platform for Biotech & Pharmaceutical Industry: KALA BIO, Inc. (Nasdaq: KALA) - FinancialContent
KALA BIO (KALA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
KALA Engages AI Technology for Advancing Psilocybin Drug Development - GuruFocus
Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate - Investing News Network
Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010 - tipranks.com
Red Light Holland Engages Kala Bio’s Researgency.AI - GlobeNewswire
Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate - TMX Newsfile
AI to speed testing of psilocybin drug PEX010 for addiction and depression - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Stock Trend Capital Highlights Younet AI’s Exclusive Biotech Partnership with KALA BIO - TipRanks
KALA BIO to launch first commercial AI agent in two weeks - Investing.com Nigeria
KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update - MarketBeat
Why Did KALA Stock Surge 25% Today? - Stocktwits
Form 144 KALA BIO For: 12 March By Investing.com - Investing.com Australia
Kala Bio chases 'Palantir for biotech' dream with new AI platform - MSN
Movement Recap: Does Dragonfly Energy Holdings Corp Equity Warrant have consistent dividend growthQuarterly Trade Report & Expert Curated Trade Ideas - baoquankhu1.vn
Kala Bio Inc (KALA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):